JP2012228272A5 - - Google Patents

Download PDF

Info

Publication number
JP2012228272A5
JP2012228272A5 JP2012187518A JP2012187518A JP2012228272A5 JP 2012228272 A5 JP2012228272 A5 JP 2012228272A5 JP 2012187518 A JP2012187518 A JP 2012187518A JP 2012187518 A JP2012187518 A JP 2012187518A JP 2012228272 A5 JP2012228272 A5 JP 2012228272A5
Authority
JP
Japan
Prior art keywords
framework
single chain
chain framework
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012187518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012228272A (ja
JP6075836B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012228272A publication Critical patent/JP2012228272A/ja
Publication of JP2012228272A5 publication Critical patent/JP2012228272A5/ja
Application granted granted Critical
Publication of JP6075836B2 publication Critical patent/JP6075836B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012187518A 2002-05-22 2012-08-28 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法 Expired - Lifetime JP6075836B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38264902P 2002-05-22 2002-05-22
US60/382,649 2002-05-22
US43825603P 2003-01-03 2003-01-03
US60/438,256 2003-01-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010060713A Division JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013019425A Division JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Publications (3)

Publication Number Publication Date
JP2012228272A JP2012228272A (ja) 2012-11-22
JP2012228272A5 true JP2012228272A5 (enExample) 2013-03-21
JP6075836B2 JP6075836B2 (ja) 2017-02-08

Family

ID=29553590

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2004506369A Withdrawn JP2006508638A (ja) 2002-05-22 2003-05-21 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2010060713A Withdrawn JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2012187518A Expired - Lifetime JP6075836B2 (ja) 2002-05-22 2012-08-28 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013019425A Expired - Lifetime JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013193935A Pending JP2013256533A (ja) 2002-05-22 2013-09-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161601A Pending JP2015214583A (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161600A Expired - Lifetime JP6261136B2 (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2017161036A Pending JP2017201990A (ja) 2002-05-22 2017-08-24 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2019009288A Expired - Lifetime JP6918033B2 (ja) 2002-05-22 2019-01-23 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2020085288A Pending JP2020171286A (ja) 2002-05-22 2020-05-14 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004506369A Withdrawn JP2006508638A (ja) 2002-05-22 2003-05-21 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2010060713A Withdrawn JP2010187678A (ja) 2002-05-22 2010-03-17 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2013019425A Expired - Lifetime JP6100544B2 (ja) 2002-05-22 2013-02-04 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2013193935A Pending JP2013256533A (ja) 2002-05-22 2013-09-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161601A Pending JP2015214583A (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2015161600A Expired - Lifetime JP6261136B2 (ja) 2002-05-22 2015-08-19 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2017161036A Pending JP2017201990A (ja) 2002-05-22 2017-08-24 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2019009288A Expired - Lifetime JP6918033B2 (ja) 2002-05-22 2019-01-23 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
JP2020085288A Pending JP2020171286A (ja) 2002-05-22 2020-05-14 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法

Country Status (14)

Country Link
US (5) US8853362B2 (enExample)
EP (5) EP2332989B1 (enExample)
JP (10) JP2006508638A (enExample)
CN (4) CN102093477B (enExample)
AU (2) AU2003238370B2 (enExample)
CA (2) CA2483285C (enExample)
CY (1) CY1114225T1 (enExample)
DK (2) DK2332989T3 (enExample)
ES (3) ES2399617T3 (enExample)
HU (1) HUE048922T2 (enExample)
NZ (1) NZ536412A (enExample)
PT (2) PT1506236E (enExample)
SI (2) SI2332989T1 (enExample)
WO (1) WO2003097697A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
EP1891110A2 (en) * 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
AU2013207650B2 (en) * 2005-06-07 2016-04-21 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2016204739C1 (en) * 2005-06-07 2017-10-19 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
AU2011265593B2 (en) * 2005-06-07 2013-08-15 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
CA2650822C (en) 2006-04-28 2017-03-14 Esbatech Ag Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
ES2603399T3 (es) 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
WO2008131575A2 (en) * 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
NZ581468A (en) * 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CN101688200B (zh) * 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
EP2197914A1 (en) 2007-09-13 2010-06-23 Delenex Therapeutics AG HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
AU2015201794B2 (en) * 2008-06-25 2017-01-19 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
AU2013202997B2 (en) * 2008-06-25 2015-01-22 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha
EP3964526A1 (en) 2008-06-25 2022-03-09 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
AU2016273957C1 (en) * 2008-06-25 2019-04-18 Novartis Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
PT2307458T (pt) * 2008-06-25 2018-07-18 Esbatech Alcon Biomed Res Unit Humanização de anticorpos de coelho utilizando uma estrutura de anticorpos universal
RU2582244C2 (ru) 2008-06-30 2016-04-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
MX2011000009A (es) 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
KR101817279B1 (ko) * 2009-02-24 2018-01-10 에스바테크 - 어 노바티스 컴파니 엘엘씨 세포-표면 항원의 면역결합제를 동정하는 방법
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2476754A1 (en) * 2011-01-14 2012-07-18 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv)
WO2013023251A1 (en) 2011-08-18 2013-02-21 Affinity Biosciences Pty Ltd Soluble polypeptides
AU2012325232B2 (en) 2011-10-20 2017-08-31 Esbatech - A Novartis Company Llc Stable multiple antigen-binding antibody
CN113234142B (zh) * 2012-08-22 2024-03-05 财团法人牧岩生命工学研究所 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用
MX374817B (es) 2012-11-05 2025-03-06 Delenex Therapeutics Ag Miembros de union para il-1 beta.
ES2895848T3 (es) 2012-12-17 2022-02-22 Cell Medica Inc Anticuerpos contra IL-1 beta
CN104884470A (zh) * 2013-02-15 2015-09-02 艾斯巴技术-诺华有限责任公司 用于cdr移植的接受体框架
WO2014127811A1 (en) 2013-02-20 2014-08-28 Esbatech - A Novartis Company Llc Acceptor framework for cdr grafting
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
SG11201803054UA (en) 2015-10-13 2018-05-30 Eureka Therapeutics Inc Antibody agents specific for human cd19 and uses thereof
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
EP3515491A4 (en) 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2019199941A1 (en) * 2018-04-10 2019-10-17 Northwestern University Extracellular vesicles comprising targeting affinity domain-based membrane proteins
WO2020069349A1 (en) * 2018-09-27 2020-04-02 Colorado State University Research Foundation Scfv's for live cell imaging and other uses
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
CA3176556A1 (en) 2020-07-16 2022-01-20 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
CA3172265A1 (en) 2021-03-10 2022-09-15 Dimitri BIELI Antibodies against tdp-43 and methods of using the same
EP4469081A1 (en) 2022-01-24 2024-12-04 Cambridge Enterprise Limited Tau therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US6828422B1 (en) * 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6262238B1 (en) 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
EP1040201A4 (en) 1997-11-28 2001-11-21 Invitrogen Corp SINGLE CHAIN MONOCLONAL ANTIBODY FUSION AGENTS THAT REGULATE IN VIVO TRANSCRIPTION
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
EP1479694B1 (en) 1999-12-28 2016-10-26 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies ScFv with defined framework that is stable in a reducing environment
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
DE10039191C1 (de) 2000-08-10 2002-01-17 Infineon Technologies Ag Hochfrequenz-Eingangsstufe

Similar Documents

Publication Publication Date Title
JP2014515602A5 (enExample)
FI3936521T3 (fi) Heterodimeerisiä proteiineja
López-Marqués et al. Structure and mechanism of ATP-dependent phospholipid transporters
JP2018531624A5 (enExample)
BRPI0813898A2 (pt) métodos para selecionar um peptídeo ou polipeptídeo resistente à protease de um repertório de peptídeo ou polipeptídeos, para produzir um repertório de peptídeos ou polipeptídeos resistentes à protease, para fabricar um peptídeo ou polipeptídeo resistente à protease, e para tratar uma doença, peptídeo ou polipeptídeo resistente à protease, domínio variável simples de imunoglobulina resistente à protease isolada, antagonista, uso de um antagonista, ácido nucleico, vetor, e, célula hospedeira.
IL258102A (en) Immunomodulatory transmembrane proteins containing domain variants of the immunoglobulin superfamily, nucleic acids encoding them, vectors and cells expressing them and uses thereof
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
Zhou et al. Structural perspective on the formation of ribonucleoprotein complex in negative-sense single-stranded RNA viruses
JP2010227108A5 (enExample)
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2016502843A5 (enExample)
JP2016185981A5 (enExample)
JP2017048194A5 (enExample)
JP2020501532A5 (enExample)
JP2013172734A5 (enExample)
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
WO2015089486A3 (en) Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2013119302A3 (en) Gh61 polypeptide variants and polynucleotides encoding same
WO2016168755A8 (en) Method for mass humanization of non-human antibodies
JP2013539454A5 (enExample)
WO2012142434A8 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
JP2017514522A5 (enExample)
JP2014511682A5 (enExample)
WO2016130628A8 (en) Griffithsin mutants
JP2012505657A5 (enExample)